PARADISE - MI

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

  • Patient Population – Patients with spontaneous AMI, LV systolic dysfunction and/or pulmonary congestion, and 1 out of 8 potential risk factors.
  • Study Description – The aim of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.
  • Sponsor –  Novartis
  • Contact Information –  (402) 384 – 2705, MPCHeartConsultantsResearch@nmhs.org
  • Clinical Trials Government Link
©2018 Heart Consultants P.C. All Rights Reserved